Pharming Group

PHARApproved

Leiden, Netherlandspharming.com

Pharming Group is a commercial-stage rare disease biopharmaceutical company with a mission to transform the lives of underserved patients. The company leverages its proven clinical development, supply chain, and commercial infrastructure to grow its existing portfolio and invest in long-term pipeline expansion. With a dual listing on Euronext Amsterdam (PHARM) and Nasdaq (PHAR), Pharming aims to become a leading global rare disease company through a combination of organic growth and strategic business development.

Market Cap

$1.1B

Focus

Biologics

PHAR · Stock Price

USD 15.36+7.49 (+95.17%)

Historical price data

AI Company Overview

Pipeline Snapshot

3 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Leniolisib	APDS	Phase 3
Leniolisib	APDS	Phase 3
Leniolisib	PIDs Linked to PI3K	Phase 2

Funding History

Total raised: $25M

Debt$25MKreos CapitalMar 15, 2020

IPOUndisclosedUndisclosedJun 15, 1998

FDA Approved Drugs

JOENJANDAMar 24, 2023

Opportunities

Key growth opportunities include expanding the global footprint and label of leniolisib in APDS (including pediatric patients), developing it for new indications in primary immunodeficiencies, advancing a pivotal program in primary mitochondrial diseases, and pursuing strategic business development to broaden the pipeline.

Risk Factors

Key risks include commercial dependence on a single product for an ultra-rare disease, clinical and regulatory risks associated with pipeline expansion into new disease areas, challenges in global market access and reimbursement for high-cost therapies, and execution risk in business development activities.

Competitive Landscape

Pharming's lead product has first-mover advantage in the ultra-rare APDS market with limited direct competition. In its pipeline expansion areas (broader PIDs, mitochondrial diseases), it will face competition from other biopharma companies targeting immune dysregulation and metabolic disorders. Its differentiation lies in its specialized rare disease infrastructure and focused development strategy.

Publications

Pipeline

FDA Approvals